Literature DB >> 17510410

Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.

Guangyu Gu1, Jialing Yuan, Marcia Wills, Susan Kasper.   

Abstract

Cancer may arise from a cancer stem/progenitor cell that shares characteristics with its normal counterpart. We report the reconstitution of the original human prostate cancer specimen from epithelial cell lines (termed HPET for human prostate epithelial/hTERT) derived from this sample. These tumors can be described in terms of Gleason score, a classification not applied to any of the transgenic mouse models currently developed to mimic human disease. Immunohistochemical and Western blot analyses indicate that they do not express androgen receptor or p63, similar to that reported for prostate stem cells. These cell lines also express embryonic stem markers (Oct4, Nanog, and Sox2) as well as early progenitor cell markers (CD44 and Nestin) in vitro. Clonally derived HPET cells reconstitute the original human tumor in vivo and differentiate into the three prostate epithelial cell lineages, indicating that they arise from a common stem/progenitor cell. Serial transplantation experiments reconstitute the tumors, suggesting that a fraction of parental or clonally derived HPET cells have self-renewal potential. Thus, this model may enhance our understanding of human tumor development and provide a mechanism for studying cancer stem/progenitor cells in differentiation, tumorigenesis, preclinical testing, and the development of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510410     DOI: 10.1158/0008-5472.CAN-06-4608

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  147 in total

1.  Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways.

Authors:  FangJun Yuan; Wenbo Zhou; Can Zou; Zhiyun Zhang; Hongsheng Hu; Zongqing Dai; YouShun Zhang
Journal:  Mol Cell Biochem       Date:  2010-06-15       Impact factor: 3.396

2.  Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.

Authors:  Murielle Mimeault; Sonny L Johansson; Jean-Pierre Henichart; Patrick Depreux; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-02-23       Impact factor: 6.261

Review 3.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

4.  Anchorage-independent culture maintains prostate stem cells.

Authors:  Xudong Shi; Jerry Gipp; Wade Bushman
Journal:  Dev Biol       Date:  2007-09-29       Impact factor: 3.582

5.  Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.

Authors:  Anne Schroeder; Andreas Herrmann; Gregory Cherryholmes; Claudia Kowolik; Ralf Buettner; Sumanta Pal; Hua Yu; Gerhard Müller-Newen; Richard Jove
Journal:  Cancer Res       Date:  2013-10-31       Impact factor: 12.701

Review 6.  microRNA and stem cell function.

Authors:  Steven Hatfield; Hannele Ruohola-Baker
Journal:  Cell Tissue Res       Date:  2007-11-07       Impact factor: 5.249

Review 7.  Current mouse and cell models in prostate cancer research.

Authors:  Xinyu Wu; Shiaoching Gong; Pradip Roy-Burman; Peng Lee; Zoran Culig
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 8.  Exploring the origins of the normal prostate and prostate cancer stem cell.

Authors:  Susan Kasper
Journal:  Stem Cell Rev       Date:  2008-09       Impact factor: 5.739

9.  Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer.

Authors:  Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal
Journal:  Mol Med       Date:  2016-09-12       Impact factor: 6.354

Review 10.  Adaptation or selection--mechanisms of castration-resistant prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.